The Association for Molecular Pathology Voices Concern with U.S. FDA Anticipated Details of Laboratory Developed Test Draft Guidance

AMP today reaffirmed its position that the vast majority of laboratory developed procedures should continue operating under the regulation of the CLIA program at the CMS and not be subject to pre-market review by the FDA, as suggested in the draft guidance notification issued to Congress on July 31, 2014.